Silence Therapeutics announces additional results from SANRECO study

Silence Therapeutics (SLN) announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera were presented at the American Society of Hematology annual Mmeeting being held in San Diego, California. Initial results from the SANRECO Phase 1 study were presented in June and showed that all doses of divesiran substantially reduced phlebotomy frequency and lowered hematocrit in 16 phlebotomy dependent PV patients regardless of baseline HCT levels. Additional data presented at ASH further support those findings and included 19 PV patients with a combined history of 79 phlebotomies prior to enrolment. Following divesiran dosing, only five phlebotomies occurred during the 18-week treatment period – all were in patients who entered the study with high baseline HCT levels. Two phlebotomies occurred in the 16-week follow-up period following the last administered dose. Consistent with results reported in June, there was a sustained reduction in HCT during the treatment period and favorable effects on indices of iron metabolism. Hepcidin levels increased and were sustained within physiological levels in all dose groups, demonstrating consistent target engagement. Importantly, divesiran continues to be well tolerated to-date with no dose-limiting toxicities.